Synthesis of some tropane-based compounds targeting colon cancer

Author:

Samir Nermin1ORCID,George Riham F2ORCID,Elrazaz Eman Z1ORCID,Ayoub Iriny M3ORCID,Shalaby ElSayed M45ORCID,Plaisier Jasper R5ORCID,Demitri Nicola5ORCID,Wink Michael6ORCID

Affiliation:

1. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, African Union Organization Street, Cairo 11566, Egypt

2. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt

3. Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, African Union Organization Street, Cairo 11566, Egypt

4. X-Ray Crystallography Lab., Physics Division, National Research Centre, Dokki, Giza 12622, Egypt

5. Elettra-Sincrotrone Trieste S.C.p.A., AREA Science Park, 34149 Basovizza, Trieste, Italy

6. Institute of Pharmacy & Molecular Biotechnology, INF 364, Heidelberg University, D-69120 Heidelberg, Germany

Abstract

Background: In continuation of a previous work concerned with the anticancer activity of some 8-alkyl-2,4-bisarylidene-8-nortropan-3-ones, this work focuses on further modification to the tropane/pyran fused skeleton aiming to obtain improved anticancer activity. Methodology: Reaction of 8-alkyl-2,4-bisarylidene-8-nortropan-3-ones 1–21 with malononitrile under basic conditions afforded tropane/pyran hybrids 22–40 and tropane/pyridine hybrids 41, 42. X-ray crystallography for compounds 22 and 41 as representative examples confirmed their structures. They were tested for their anticancer activity in the HCT116 cell line. Results: Compounds 26 and 33 were the most active compounds with IC50 values of 3.39 and 0.01 μM against HCT116. Moreover, they revealed cyclin-dependent kinase-2 (CDK2) inhibition with IC50 = 104.91 and 49.13 nM, respectively. Furthermore, molecular docking of compounds 26 and 33 in the active site of CDK2 confirmed the obtained results. Conclusion: Tropane/pyran scaffold can be considered as a promising core for anticancer agents acting as CDK2 inhibitors.

Funder

Science and Technology Development Fund in Egypt

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3